Core Insights - The Hainan Boao Lecheng International Medical Tourism Pilot Zone has achieved significant progress in its special drug and medical device policy, with 476 imported special drugs and devices as of April 30, 2025, including 175 drugs and 301 devices [1] Group 1: Policy Advantages - The Lecheng Pilot Zone has four core policy advantages: special drug and device policy, real-world research policy for drugs and devices, real-world research policy for medical insurance, and special operation policy for public hospitals [1] - The special drug and device policy allows the import and use of new drugs and devices that have not yet been approved in China, enabling patients to access the latest global medical innovations more quickly and conveniently [1] Group 2: Future Plans - The Lecheng Medical Supervision Bureau plans to focus on "medical" as the core and actively serve the introduction of special drugs and devices through a traceability platform, transitioning from passive approval to proactive service [2] - The zone aims to introduce a full range of special drugs and devices related to specific diseases and specialties, creating a comprehensive multidisciplinary center for disease management [2] - The plan includes expanding the entire industrial chain of special drugs and devices through real-world data research and medical-engineering transformation, positioning Lecheng as a new highland for drug and device research and development [2] Group 3: Regulatory Commitment - The special drug and device policy is regarded as Lecheng's "golden signboard," with a commitment to maintaining medical safety, ethical safety, and policy safety [3] - The Lecheng Medical Supervision Bureau will continue to support the application of special drugs and devices and real-world data research while strengthening regulation to ensure medical safety [3]

将向科创板眼科医疗设备"第一股"发起冲击。 本文为IPO早知道原创 作者｜Stone Jin 微信公众号｜ipozaozhidao 据IPO早知道消息，图湃医疗日前完成由社保基金中关村自主创新专项基金(由君联资本担任管理 人)、北京机器人产业投资基金、启明创投共同投资的总规模达5亿元人民币级别E轮融资。 这是继2024年6月完成D轮融资后，图湃医疗一年内再受顶级投资机构青睐。 ， 也是 国内 眼科医 疗设备领域历史上已公开一级市场投融资事件中单笔金额最高的融资 ，所融资金将持续用于图湃医 疗丰富产品矩阵及加强全球范围的市场布局等。 在完成本次E轮融资后，图湃医疗将向科创板眼科医疗设备"第一股"发起冲击。 图湃医疗始于清华大学电子工程系的科技成果转化。公司创始人、清华大学霍力教授2008年在约翰 霍普金斯大学做博士后期间就开始从事扫频OCT研究，师从Xingde Li教授，后者是OCT发明人 James G. Fujimoto教授的学生。在国家自然科学基金等多个科研项目的支持下，霍力教授带领团 队实现了一系列关键底层技术的突破和自主化。 图湃医疗成立后，眼科OCT在北京清华工业开发研究院医工转化体系中，迅速完成 ...